Clinical pharmacokinetics (PK) and translational PK-pharmacodynamic (PD) modeling and simulation to predict antitumor response of various dosing schedules to guide the selection of a recommended phase II dose (RP2D) and schedule for the investigational agent MLN0128.
Chirag G. Patel
Employment or Leadership Position - Millennium
Mayank Patel
Employment or Leadership Position - Millennium
Arijit Chakravarty
Employment or Leadership Position - Millennium
Esha A. Gangolli
Employment or Leadership Position - Millennium
Stock Ownership - Novartis; Takeda
Elly Barry
Employment or Leadership Position - Millennium
Eric H. Westin
Employment or Leadership Position - Millennium
Katti Jessen
Employment or Leadership Position - Takeda
Stock Ownership - MLN0128
Shripad D. Chitnis
Employment or Leadership Position - Millennium
Jeffrey R. Infante
No relevant relationships to disclose
Michael S. Gordon
Research Funding - Millennium
Teresa Macarulla
No relevant relationships to disclose
Andres Cervantes-Ruiperez
No relevant relationships to disclose
Shadia Ibrahim Jalal
No relevant relationships to disclose
Karthik Venkatakrishnan
Employment or Leadership Position - Millennium